Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ROXYBOND vs ALFENTANIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ROXYBOND is an immediate-release formulation of oxycodone, a full mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system (CNS), inhibiting ascending pain pathways and altering pain perception and emotional response to pain.
Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Analgesic adjunct during general anesthesia,Induction of anesthesia,Maintenance of anesthesia for short surgical procedures,Off-label: Procedural sedation in monitored settings
Immediate-release oral tablets: 5-15 mg every 4-6 hours as needed for pain. Maximum 60 mg/day. For extended-release: 10-20 mg every 12 hours, adjusted based on prior opioid use.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.
3.5–6 hours; prolonged in renal impairment, hepatic impairment, or elderly patients, requiring dose adjustment.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours). Clinically, context-sensitive half-time is short (~40 min after 3-hour infusion) due to rapid redistribution and metabolism.
Primarily hepatic via CYP3A4 and to a lesser extent CYP2D6. Oxycodone is metabolized to noroxycodone (via CYP3A4), oxymorphone (via CYP2D6), and other minor metabolites.
Alfentanil is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4, through oxidative N-dealkylation and O-demethylation to inactive metabolites.
Primarily renal (90% as free drug and glucuronide conjugates). Fecal elimination accounts for <10%.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; metabolites (mainly noralfentanil) excreted renally. Biliary/fecal excretion of metabolites accounts for ~30%.
Approximately 20–30%, primarily to albumin.
~92% bound primarily to alpha-1-acid glycoprotein (AAG) and albumin.
2.6–4.0 L/kg, indicating extensive tissue distribution (e.g., brain, lungs, liver).
Vd: 0.4–1.0 L/kg (mean ~0.75 L/kg). Moderate Vd reflecting rapid distribution to tissues, especially brain and muscle.
Oral: 10–20% (extensive first-pass metabolism); intranasal: 30–50%; intravenous: 100%.
IV: 100%. IM: ~90%. Epidural: ~30–50% due to local uptake and redistribution. No significant oral bioavailability.
For GFR 30-59 m L/min: reduce dose by 25% and increase dosing interval. For GFR <30 m L/min: reduce dose by 50% and administer every 12 hours. Avoid in ESRD.
GFR 10-50 m L/min: administer with caution, consider dose reduction of 25-50%; GFR <10 m L/min: reduce dose by 50% and extend dosing interval.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% and increase interval. Child-Pugh Class C: avoid use.
Child-Pugh class A: no adjustment needed; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75%.
Weight-based dosing: 0.1-0.2 mg/kg/dose every 4-6 hours as needed. Maximum single dose: 5 mg for <50 kg, 10 mg for ≥50 kg.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-2 mcg/kg/min. For neonates, reduce dose by 30-50% due to immature clearance.
Start at lowest effective dose (2.5-5 mg every 4-6 hours). Titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor renal function.
Reduce initial IV bolus by 30-50% to 3-10 mcg/kg; titrate carefully; monitor for prolonged sedation and respiratory depression.
Addiction, Abuse, and Misuse; Life-Threatening Respiratory Depression; Accidental Ingestion; Neonatal Opioid Withdrawal Syndrome; Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants; and Risk of Medication Errors (due to immediate-release formulation, which requires careful dose conversion from other oxycodone products).
Risk of respiratory depression: Alfentanil can cause severe, life-threatening, or fatal respiratory depression. Monitor for respiratory depression, especially during initiation or following dose increases. Accidental ingestion of even one dose can be fatal. Concomitant use with central nervous system depressants (e.g., benzodiazepines, alcohol) may increase risk. Alfentanil is an opioid agonist and a Schedule II controlled substance with high potential for abuse and addiction.
Life-threatening respiratory depression, especially in elderly, cachectic, or debilitated patients and those with pre-existing respiratory conditions.,Risk of opioid-induced hyperalgesia.,Adrenal insufficiency with prolonged use.,Severe hypotension, including orthostatic hypotension, in patients with compromised ability to maintain blood pressure.,Risk of serotonin syndrome with concomitant serotonergic drugs.,Seizures in patients with seizure disorders or taking other seizure threshold-lowering drugs.,Avoid abrupt discontinuation; taper dose to prevent withdrawal syndrome.
Respiratory depression: Potentially fatal; monitor oxygenation and ventilation.,Abuse potential: Schedule II controlled substance; risk of addiction, abuse, and diversion.,Concomitant use with CNS depressants: Increases risk of profound sedation, respiratory depression, coma, and death; limit use or monitor closely.,Geriatric and cachectic patients: Increased sensitivity; reduce initial dose.,Hepatic impairment: Alfentanil clearance is reduced in patients with cirrhosis; consider dose adjustment.,Bradycardia and hypotension: Use with caution in patients with hypovolemia or reduced cardiac reserve.,Serotonin syndrome: Risk with concurrent serotonergic drugs (e.g., MAOIs, SSRIs, triptans); monitor for symptoms.,Withdrawal: Prolonged use may lead to physical dependence; taper dose gradually.
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity to oxycodone or any component of the formulation
Hypersensitivity to alfentanil, fentanyl, or any opioid,Significant respiratory depression (e.g., acute asthma, COPD in acute exacerbation),Acute or severe bronchial asthma,Suspected or known paralytic ileus,MAO inhibitor use within 14 days (serotonin syndrome risk),Myasthenia gravis (relative contraindication due to risk of respiratory muscle weakness),Morbid obesity with sleep apnea (relative contraindication; increased risk of respiratory depression)
Avoid alcohol and any alcohol-containing foods or beverages. Grapefruit and grapefruit juice may increase oxycodone levels; avoid concurrent use.
No significant food interactions known. Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 metabolism, potentially prolonging effects.
ROXYBOND (oxycodone) is an opioid agonist. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Chronic use may lead to fetal dependence and neonatal opioid withdrawal syndrome (NOWS) after delivery. Avoid during labor due to respiratory depression in the newborn.
Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid prolonged use or high doses near term; use during labor may cause respiratory depression in neonate.
Small amounts of oxycodone are excreted into breast milk. The milk-to-plasma (M/P) ratio is approximately 3:1. Use with caution, especially in mothers who are ultrarapid metabolizers of CYP2D6, as this increases risk of toxicity in the infant. Monitor infant for drowsiness, poor feeding, and respiratory depression.
Alfentanil is excreted into breast milk in very low concentrations; estimated relative infant dose is low (<2% of maternal weight-adjusted dose). M/P ratio not determined in humans. Compatible with breastfeeding with caution; monitor infant for drowsiness, feeding difficulties.
Pregnancy may increase oxycodone clearance due to expanded blood volume and enhanced hepatic metabolism. Dose adjustments may be needed: consider increasing the frequency or dose based on pain control and tolerance. Avoid high doses near term; use lowest effective dose. Monitor for respiratory depression in both mother and neonate.
Pregnancy can alter alfentanil pharmacokinetics: increased volume of distribution, decreased plasma clearance, prolonged elimination half-life. Dose reduction may be needed for prolonged use; titrate to effect. During labor, use smallest effective dose.
ROXYBOND (oxycodone hydrochloride) is an immediate-release opioid agonist indicated for acute pain severe enough to require an opioid. Its unique formulation resists crushing and dissolution, but it can still be abused intravenously. Be aware of the risk of respiratory depression, particularly in opioid-naive patients. Use with caution in patients with respiratory disease, or in elderly or debilitated patients. Tolerance and dependence can develop; monitor for signs of misuse. Naloxone is the reversal agent. Not indicated for as-needed use; prescribe the lowest effective dose for the shortest possible duration.
Alfentanil is a potent, short-acting synthetic opioid (4-5 times more potent than fentanyl) with rapid onset (1-2 min) and brief duration (5-10 min). Primarily used for induction and maintenance of anesthesia, especially in short procedures. Requires careful monitoring of respiratory depression and chest wall rigidity, particularly during rapid IV administration. Hepatic metabolism (CYP3A4) affected by liver disease; reduce dose. Decrease dose in elderly and hypovolemic patients. Not recommended for chronic pain due to short half-life.
Take exactly as prescribed; do not break, crush, chew, or dissolve the tablet as it can cause rapid release and fatal overdose.,Do not consume alcohol or any alcohol-containing products while taking ROXYBOND.,Store securely out of sight and reach of children and pets; properly dispose of unused tablets via a drug take-back program.,Side effects include constipation, nausea, dizziness, and drowsiness; contact your healthcare provider if you experience difficulty breathing or extreme sleepiness.,Avoid driving or operating heavy machinery until you know how ROXYBOND affects you.,Do not share this medication with others; it can cause addiction and death.,Inform your doctor about all other medications, especially sedatives, tranquilizers, or antidepressants.
This medication causes drowsiness and dizziness; avoid driving or operating machinery for at least 24 hours after administration.,Report any difficulty breathing, chest tightness, or feeling faint immediately.,Alfentanil is used only in hospital settings under direct supervision of healthcare professionals.,Inform your doctor if you have a history of liver disease, lung disease, or drug/alcohol abuse.,Do not consume alcohol or other sedatives while under the effects of alfentanil.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ROXYBOND vs ALFENTANIL, answered by our medical review team.
ROXYBOND is a Opioid Analgesic that works by ROXYBOND is an immediate-release formulation of oxycodone, a full mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system (CNS), inhibiting ascending pain pathways and altering pain perception and emotional response to pain.. ALFENTANIL is a Opioid Analgesic that works by Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ROXYBOND and ALFENTANIL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ROXYBOND is: Immediate-release oral tablets: 5-15 mg every 4-6 hours as needed for pain. Maximum 60 mg/day. For extended-release: 10-20 mg every 12 hours, adjusted based on prior opioid use.. The standard adult dose of ALFENTANIL is: Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ROXYBOND and ALFENTANIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ROXYBOND is classified as Category C. ROXYBOND (oxycodone) is an opioid agonist. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Chr. ALFENTANIL is classified as Category C. Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.